Hyperuricemia and gout.
Hyperuricemia and gout.
复制标题
DOI：
10.1007/s11926-003-0072-y
复制
发表时间：
2003-06-01
影响因子：
5
通讯作者：
Liote, Frederic
中科院分区：
文献类型：
--
作者：
Liote, Frederic
对于临床医生来说，痛风并不是一种新疾病；尽管如此，仍有许多秘密有待发现，以提高对尿酸代谢和尿酸一钠结晶引起的炎症的认识。这篇文献综述将集中于对特发性高尿酸血症的发病机制以及继发性高尿酸血症和痛风的新见解。在急性痛风的病理生理学方面也有重要的进展，特别是作为一个自我限制的过程(从单核细胞到巨噬细胞的转换，过氧化物酶体增殖物激活的受体-γ和一氧化氮)，以及慢性痛风关节病。用于治疗高尿酸血症和痛风的武器可能已经通过氯沙坦或非诺贝特，以及未来的尿酸氧合酶聚乙二醇20和肾脏处理调节分子而得到改善。最后，在心血管疾病的预防和治疗中，也可以考虑控制高尿酸血症。
Gout is not a new disease for clinicians; nevertheless, there are still many secrets awaiting discovery for improving knowledge with respect to uric acid metabolism and monosodium urate crystal-induced inflammation. This review of the literature will focus on new insights on the pathogenesis of idiopathic hyperuricemia, and on secondary hyperuricemia and gout. There are also important advances on the pathophysiology of acute gout, especially as a self-limited process (switch from monocyte to macrophage, peroxisome proliferator activated receptor-gamma, and nitric oxide), but also of chronic gouty arthropathy. Armaments for treating hyperuricemia and gout may be already improved by losartan or fenofibrate and, in the future, by urate oxydase-polyethylene glycol 20 and renal handling regulatory molecules. Finally, control of hyperuricemia may also be considered in the prevention and treatment of cardiovascular disease.